Posted by admin on Nov 1, 2013 in |
Benign Prostatic Hyperplasia (BPH) is a common progressive disease among men, with an incidence that is high among elderly. Velvanga parpam (VP) has been employed as traditional remedy for Benign Prostatic Hyperplasia (BPH) which is a herbo mineral formulation. As a mandate, steps were taken to evaluate safety profile of VP in rats and mice following OECD guidelines. Acute toxicity studies, different doses of VP were administered orally to rats once daily for one week. Sub-acute toxicity studies were carried in four different groups in which VP was administrated orally to rats once daily for 28 days in various doses ranging from 2.5, 5, 10 Mg/kg for mice respectively. Detailed hematological, biochemical, necropsy and histopathological evaluation of organs was performed for all animals. The VP was well tolerated and no toxic manifestations were seen in any animal. Histopathological analysis revealed that Spleen, Testes, Pancreas, Lung, Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues of treated groups did not show any signs of toxicity. Mortality observed in highdose....
Read More
Posted by admin on Nov 1, 2013 in |
The aim of this research wok is to formulate and evaluate Ciprofloxacin solid dispersions system by using the different techniques. This will increase the solubility of the drug or Ciprofloxacin and give the immediate release of the drug from the formulations. The main objective is to formulate a drug product as immediate release oral solid dosage form of Ciprofloxacin solid dispersion system which is considered to be stable, robust quality and enhanced dissolution rate. To optimize the method of manufacture by formulate the Ciprofloxacin solid dispersion system by various techniques like Physical mixing, Co-grinding, Kneading and solvent evaporation techniques. The disintegrating agent used in the present study is Crosscarmellose sodium. Among the four different techniques used for preparation of solid dispersions solvent evaporation technique has shown the increase in dissolution rate that is the Trail-5 was found to have a faster solubility and dissolution property which was prepared by using Crosscarmellose sodium as a disintegrant in the ratio of...
Read More
Posted by admin on Nov 1, 2013 in |
Microwave assisted organic synthesis (MAOS) has emerged as frontier in pharmaceutical research for synthesis of newer drugs and implementing GREEN chemistry. Arylacetamides are pharmaceutically interesting as they show various biological activities such as analgesic, local anesthetic, antiarthritic, antiarrhythmic activities, etc. In arylacetamides the nature of aromatic ring and its substituent is primary determinant for its activity. To serve this purpose, we have decided to substitute arylacetamide with benzotriazole which may exploit the analgesic potential of newly synthesized derivatives i.e N-(Alkyl or Aryl)-2-(1H-benzotriazol-1-yl)-acetamides and thus it may be helpful in reducing the pain without having side effect of...
Read More
Posted by admin on Nov 1, 2013 in |
The aim of present work is to develop and validate simple, sensitive, economical and accurate Spectrophotometric methodhas been developed for determination of Maraviroc in pure form and in pharmaceutical formulations. Maraviroc in Phosphate buffer pH 7.4 shows maximum absorbance at 210 nm. Beer’s law was obeyed in the concentration range of 5-25 µg/mL, The LOD and LOQ were found to be 0.10428 μg/ml and 0.315 μg/ml respectively. A recovery of Maraviroc in tablet formulation was observed in the range of 100.70-103.90%. Percentages assay of Maraviroc in tablet was more than 99.73%. The proposed method is precise simple, accurate, precise, economical and robust and can be used for routine analysis of Maraviroc in bulk and pharmaceutical...
Read More
Posted by admin on Nov 1, 2013 in |
The present study was carried out to assess the pharmacokinetic drug interaction between nebivolol and cefixime following single oral dose administration in hypertensive patients. Therapeutic dose of nebivolol alone and combination with cefixime were administered to a separate group of hypertensive patients. Serial blood samples were collected at pre-dose (0.0) to 48 h post-dose following each treatment to characterize the pharmacokinetic parameters. The plasma nebivolol concentrations were estimated by a sensitive liquid chromatographic mass spectrometry (LC-MS) method. Mean (SD) of AUC0-t (ng.h/mL) and AUC0–∞ (ng.h/mL) for nebivolol given as a combination versus nebivolol alone is 39.24 (6.96) vs. 17.29 (4.60) and 45.30 (6.70) vs. 24.42 (5.08) respectively. Corresponding values for Cmax (ng/mL) is 2.98 (0.47) vs. 3.09 (0.37). Cefixime significantly increased the extent of exposure of nebivolol when used in combination. There was minor change in the peak exposure and elimination parameters. The results indicate that there observed to be a pharmacokinetic interaction when nebivolol is administered in combination with cefixime. Hence, the combination is contraindicated or used with...
Read More
